Modeling age-specific incidence of colon cancer via niche competition.
Journal
PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
03
09
2021
accepted:
18
07
2022
revised:
31
08
2022
pubmed:
20
8
2022
medline:
9
9
2022
entrez:
19
8
2022
Statut:
epublish
Résumé
Cancer development is a multistep process often starting with a single cell in which a number of epigenetic and genetic alterations have accumulated thus transforming it into a tumor cell. The progeny of such a single benign tumor cell expands in the tissue and can at some point progress to malignant tumor cells until a detectable tumor is formed. The dynamics from the early phase of a single cell to a detectable tumor with billions of tumor cells are complex and still not fully resolved, not even for the well-known prototype of multistage carcinogenesis, the adenoma-adenocarcinoma sequence of colorectal cancer. Mathematical models of such carcinogenesis are frequently tested and calibrated based on reported age-specific incidence rates of cancer, but they usually require calibration of four or more parameters due to the wide range of processes these models aim to reflect. We present a cell-based model, which focuses on the competition between wild-type and tumor cells in colonic crypts, with which we are able reproduce epidemiological incidence rates of colon cancer. Additionally, the fraction of cancerous tumors with precancerous lesions predicted by the model agree with clinical estimates. The correspondence between model and reported data suggests that the fate of tumor development is majorly determined by the early phase of tumor growth and progression long before a tumor becomes detectable. Due to the focus on the early phase of tumor development, the model has only a single fit parameter, the time scale set by an effective replacement rate of stem cells in the crypt. We find this effective rate to be considerable smaller than the actual replacement rate, which implies that the time scale is limited by the processes succeeding clonal conversion of crypts.
Identifiants
pubmed: 35984850
doi: 10.1371/journal.pcbi.1010403
pii: PCOMPBIOL-D-21-01619
pmc: PMC9432715
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1010403Déclaration de conflit d'intérêts
The authors (A.V.-B., S.L., D.H., R.M.) have declared that no competing interests exist.
Références
PLoS Comput Biol. 2015 Dec 10;11(12):e1004662
pubmed: 26658166
Proc Natl Acad Sci U S A. 2020 Aug 25;117(34):20681-20688
pubmed: 32788368
Nat Genet. 2016 Mar;48(3):238-244
pubmed: 26780609
Best Pract Res Clin Gastroenterol. 2001 Dec;15(6):983-98
pubmed: 11866488
Surg Radiol Anat. 2002 Dec;24(5):290-4
pubmed: 12497219
Cell Stem Cell. 2018 Jun 01;22(6):909-918.e8
pubmed: 29779891
Dtsch Arztebl Int. 2021 Apr 23;118(16):281-287
pubmed: 34180790
Science. 2010 Nov 5;330(6005):822-5
pubmed: 20929733
Nat Biotechnol. 2022 May;40(5):720-730
pubmed: 34980912
Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16284-9
pubmed: 18936480
PLoS Comput Biol. 2017 Mar 13;13(3):e1005431
pubmed: 28288156
Science. 2015 Jan 2;347(6217):78-81
pubmed: 25554788
Nat Genet. 2015 Mar;47(3):209-16
pubmed: 25665006
Am J Pathol. 2004 Apr;164(4):1337-46
pubmed: 15039221
Gastroenterology. 2018 Nov;155(5):1383-1391.e5
pubmed: 30031768
Trends Genet. 1993 Apr;9(4):138-41
pubmed: 8516849
Clin Colon Rectal Surg. 2008 Nov;21(4):247-55
pubmed: 20011435
CA Cancer J Clin. 2014 Mar-Apr;64(2):104-17
pubmed: 24639052
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376186
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4828-33
pubmed: 19261858
Clin Gastroenterol Hepatol. 2009 Jul;7(7):770-5; quiz 711
pubmed: 19268269
J Theor Biol. 2001 Jun 7;210(3):337-43
pubmed: 11397134
PLoS One. 2016 Mar 10;11(3):e0151098
pubmed: 26963717
Annu Rev Genet. 2016 Nov 23;50:347-369
pubmed: 27686281
Cell Stem Cell. 2014 Dec 4;15(6):692-705
pubmed: 25479747
Clin Cancer Res. 2013 Feb 15;19(4):764-72
pubmed: 23209033
Ann Appl Probab. 2015 Feb;25(1):104-115
pubmed: 26430352
J Clin Invest. 2007 Jan;117(1):60-9
pubmed: 17200707
Nat Ecol Evol. 2022 Feb;6(2):207-217
pubmed: 34949822
Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1350-7
pubmed: 21558495
Gastrointest Endosc. 1994 Jan-Feb;40(1):106-9
pubmed: 8163112
Br J Cancer. 1954 Mar;8(1):1-12
pubmed: 13172380
Front Oncol. 2021 Mar 23;11:558040
pubmed: 33833981
Cancer. 1992 Feb 15;69(4):883-8
pubmed: 1735079
Cell Mol Gastroenterol Hepatol. 2017 Feb 20;3(3):331-338
pubmed: 28462375
Cell Rep. 2014 Aug 21;8(4):940-7
pubmed: 25127143
Nat Rev Cancer. 2008 Jun;8(6):415-24
pubmed: 18480839
JAMA Netw Open. 2020 Jan 3;3(1):e1920407
pubmed: 32003823
Cancer Inform. 2010 Aug 24;9:179-88
pubmed: 20838610
BMC Public Health. 2015 Aug 18;15:789
pubmed: 26282269
Cancer Res. 2013 Feb 1;73(3):1086-96
pubmed: 23054397
Science. 1987 Oct 9;238(4824):193-7
pubmed: 2889267
Eur J Cancer. 2015 Jul;51(10):1346-53
pubmed: 25908273
J Theor Biol. 2008 Sep 21;254(2):229-38
pubmed: 18640693
JAMA Surg. 2015 Jan;150(1):17-22
pubmed: 25372703
PLoS Comput Biol. 2020 Feb 5;16(2):e1007552
pubmed: 32023238
Am J Pathol. 2004 Apr;164(4):1369-77
pubmed: 15039224
Cancer Inform. 2009 Aug 04;7:183-97
pubmed: 19718452
Cancer Res. 2010 Jul 1;70(13):5419-29
pubmed: 20530677
Cell Stem Cell. 2018 Nov 1;23(5):677-686.e4
pubmed: 30269903
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
World J Gastroenterol. 2013 Jul 21;19(27):4277-88
pubmed: 23885138
Front Oncol. 2019 Jan 10;8:668
pubmed: 30687642
Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15095-100
pubmed: 12415112
Cancer Causes Control. 2009 Aug;20(6):935-44
pubmed: 19294523
Br J Cancer. 2004 Dec 13;91(12):1983-9
pubmed: 15599380
Expert Rev Gastroenterol Hepatol. 2015 Feb;9(2):237-44
pubmed: 25155348
Development. 2014 Mar;141(5):988-1000
pubmed: 24550108
PLoS One. 2011;6(10):e25978
pubmed: 21998737
World J Hepatol. 2015 Nov 8;7(25):2603-9
pubmed: 26557953